EUVIMEDEUVIMED entdecken
Crossref

Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway

Juan Nie, Hequn Jiang, Runyu Zhou, Ruichen Gong, Wenli Xu, Ping Zhang, Ling Lu, Lin Lyu

Medical Oncology · 20.04.2026 · 43 (5)

DOI: 10.1007/s12032-026-03293-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 20.04.2026. Verfasst von Juan Nie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sich…. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Drug Resistance, Neoplasm, MAP Kinase Signaling System. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Chengdu Municipal Science and Technology Program, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin (DDP) is a widely used chemotherapeutic agent for ovarian cancer (OC) therapy. However, the adverse effects and frequent resistance to DDP make its therapeutic efficacy suboptimal. Combination treatment with an agent capable of overcoming DDP resistance may be a promising solution. Here, we conducted a drug library screen for agents that increase DDP efficiency in a trained DDP-resistant OC cell line (SKOV3/DDP). Diosmetin (Dio), a natural flavonoid abundant in olive leaves and citrus fruits, was identified to synergize with DDP to reduce OC cell growth through apoptosis both in vitro and in vivo, as evidenced by increased expression of the proapoptotic proteins Cleaved-Caspase3 and Cleaved-PARP, as well as decreased expression of the antiapoptotic protein BCL-2 in SKOV3/DDP cells. Mechanistically, compared with Dio or DDP treatment alone, combined Dio and DDP treatment suppressed the MAPK signaling pathway, represented by reduced phosphorylation of JNK, ERK, and P38. These findings demonstrated that Dio potentiates the anticancer effects of DDP both in vitro and in vivo, indicating that Dio is a promising adjuvant for OC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinOvarian NeoplasmsDrug Resistance, NeoplasmMAP Kinase Signaling SystemFlavonoidsAntineoplastic AgentsFemaleHumansAnimalsApoptosisCell Line, TumorMiceXenograft Model Antitumor AssaysCell ProliferationDrug SynergismMice, Nude

Stichwörter der Autor:innen

ApoptosisCisplatinDiosmetinMAPK pathwayOvarian cancer

Substanzen

CisplatindiosmetinFlavonoidsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China.
  • South China Hospital of Shenzhen University, Shenzhen, 518100, Guangdong, People's Republic of China.
  • Clinical Medical College, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China.
  • Department of Gynecology and Obstetrics, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China. linglu100@163.com.
  • Department of Gynecology and Obstetrics, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China. linlyu@yeah.net.

Förderung

  • Chengdu Municipal Science and Technology Program
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Nie, J., Jiang, H., Zhou, R., Gong, R., Xu, W., Zhang, P., Lu, L., & Lyu, L. (2026). Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway. Medical Oncology, 43(5). https://doi.org/10.1007/s12032-026-03293-8

Vancouver

Nie J, Jiang H, Zhou R, Gong R, Xu W, Zhang P, et al. Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway. Medical Oncology. 2026;43(5). doi:10.1007/s12032-026-03293-8

BibTeX
@article{Nie2026,
  author = {Nie, Juan and Jiang, Hequn and Zhou, Runyu and Gong, Ruichen and Xu, Wenli and Zhang, Ping and Lu, Ling and Lyu, Lin},
  title = {Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway},
  journal = {Medical Oncology},
  year = {2026},
  volume = {43},
  number = {5},
  doi = {10.1007/s12032-026-03293-8}
}
Kostenlos starten →